Kairos Pharma, Ltd. (NYSE American: KAPA) announced the expansion of its Phase 2 prostate cancer trial sites to include the University of Utah and City of Hope. This information was provided in a letter to stockholders from CEO John Yu, M.D., dated April 24, 2025.
These new sites join Cedars Sinai Hospital in Los Angeles, where the trials are already being conducted. The expansion aims to accelerate patient enrollment for the ongoing Phase 2 trial of ENV105 in metastatic castration-resistant prostate cancer.
The company is also focused on identifying and confirming biomarkers as part of these trials to pinpoint patients for whom the combined therapy may prove most effective. Adding these prominent research institutions supports the broader patient population and biomarker identification efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.